Compare HIT & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | MCRB |
|---|---|---|
| Founded | 1964 | 2010 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 78.0M |
| IPO Year | N/A | 2015 |
| Metric | HIT | MCRB |
|---|---|---|
| Price | $0.99 | $7.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $3.25 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 274.6K | 33.2K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $41.00 | N/A |
| Revenue Next Year | $69.63 | N/A |
| P/E Ratio | $52.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $6.56 |
| 52 Week High | $4.01 | $29.98 |
| Indicator | HIT | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 35.72 | 42.57 |
| Support Level | N/A | $7.33 |
| Resistance Level | $1.81 | $9.53 |
| Average True Range (ATR) | 0.13 | 0.41 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 20.37 | 18.17 |
Health In Tech Inc is an AI-enabled insurance technology platform company that offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. By removing friction and complexities, it streamlines the underwriting, sales, and service process for insurance companies, licensed brokers, Managing General Underwriter (MGUs), and third-party administrators (TPAs). The company's platform serves as a marketplace for brokers, TPAs, MGUs and carriers with self-funded health insurance options for employers. The platform includes functions such as plan customization, stop-loss quoting, underwriting, claims administration, and reporting integration.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.